Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1.
The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 microM) and FOS (37.5 microM) in the presence of 14.8 and 6.9 microM of 6b, respectively.
Talarico
Laura B
LB
Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina.
Castilla
Viviana
V
Ramirez
Javier A
JA
Galagovsky
Lydia R
LR
Wachsman
Mónica B
MB
D000212:Acyclovir / Q000494:pharmacology*; D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D002522:Chlorocebus aethiops; D002778:Cholestanones / Q000737:chemistry / Q000494:pharmacology*; D004357:Drug Synergism; D017245:Foscarnet / Q000494:pharmacology*; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D015394:Molecular Structure
C493970:3-bromo-5,22,23-trihydroxystigmastan-6-one; D000998:Antiviral Agents; D002778:Cholestanones; D017245:Foscarnet; D000212:Acyclovir